Literature DB >> 24548822

Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice.

Simona Bertoni1, Valentina Arcaro2, Valentina Vivo2, Alberto Rapalli2, Massimiliano Tognolini2, Anna Maria Cantoni3, Francesca Saccani2, Lisa Flammini2, Giuseppe Domenichini2, Vigilio Ballabeni2, Elisabetta Barocelli2.   

Abstract

Intestinal ischemia and reperfusion (I/R) is a potentially life-threatening disease, ensuing from various clinical conditions. Experimentally, either protective or detrimental roles have been attributed to 5-HT in the functional and morphological injury caused by mesenteric I/R. Recently, we proved the involvement of 5-HT2A receptors in the intestinal dysmotility and leukocyte recruitment induced by 45min occlusion of the superior mesenteric artery (SMA) followed by 24h reperfusion in mice. Starting from these premises, the aim of our present work was to investigate the role played by endogenous 5-HT in the same experimental model where 45min SMA clamping was followed by 5h reflow. To this end, we first observed that ischemic preconditioning before I/R injury (IPC+I/R) reverted the increase in 5-HT tissue content and in inflammatory parameters induced by I/R in mice. Second, the effects produced by intravenous administration of 5-HT1A ligands (partial agonist buspirone 10mgkg(-1), antagonist WAY100135 0.5-5mgkg(-1)), 5-HT2A antagonist sarpogrelate (10mgkg(-1)), 5-HT3 antagonist alosetron (0.1mgkg(-1)), 5-HT4 antagonist GR125487 (5mgkg(-1)) and 5-HT re-uptake inhibitor fluoxetine (10mgkg(-1)) on I/R-induced inflammatory response were investigated in I/R mice and compared to those obtained in sham-operated animals (S). Our results confirmed the significant role played by 5-HT2A receptors not only in the late but also in the early I/R-induced microcirculatory dysfunction and showed that blockade of 5-HT1A receptors protected against the intestinal leukocyte recruitment, plasma extravasation and reactive oxygen species formation triggered by SMA occlusion and reflow. The ability of α7 nicotinic receptor (α7nAchR) antagonist methyllycaconitine (5mgkg(-1)) to counteract the beneficial action provided by buspirone on I/R-induced neutrophil infiltration suggests that the anti-inflammatory effect produced by 5-HT1A receptor antagonism could be partly ascribed to the indirect activation of α7nAch receptors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT(1A) receptor; Buspirone; Ischemic preconditioning; Mesenteric ischemia/reperfusion; Serotonin; α7 nicotinic receptor

Mesh:

Substances:

Year:  2014        PMID: 24548822     DOI: 10.1016/j.phrs.2014.02.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  4 in total

1.  Exosomes Derived from BMSCs Ameliorate Intestinal Ischemia-Reperfusion Injury by Regulating miR-144-3p-Mediated Oxidative Stress.

Authors:  Guangru Zhang; Zhanhai Wan; Zhenzhen Liu; Disheng Liu; Zhiyu Zhao; Yufang Leng
Journal:  Dig Dis Sci       Date:  2022-05-27       Impact factor: 3.487

2.  Regulation of Expression of Cannabinoid CB2 and Serotonin 5HT1A Receptor Complexes by Cannabinoids in Animal Models of Hypoxia and in Oxygen/Glucose-Deprived Neurons.

Authors:  Jaume Lillo; Iu Raïch; Laura Silva; David A Zafra; Alejandro Lillo; Carlos Ferreiro-Vera; Verónica Sánchez de Medina; José Martínez-Orgado; Rafael Franco; Gemma Navarro
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

3.  Dexmedetomidine Ameliorated Cognitive Dysfunction Induced by Intestinal Ischemia Reperfusion in Mice with Possible Relation to the Anti-inflammatory Effect Through the Locus Coeruleus Norepinephrine System.

Authors:  Gang Li; Jun Zhou; Jicheng Wei; Bin Liu
Journal:  Neurochem Res       Date:  2022-08-09       Impact factor: 4.414

4.  Dual Role of Endogenous Serotonin in 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis.

Authors:  Alberto Rapalli; Simona Bertoni; Valentina Arcaro; Francesca Saccani; Andrea Grandi; Valentina Vivo; Anna M Cantoni; Elisabetta Barocelli
Journal:  Front Pharmacol       Date:  2016-03-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.